---
figid: PMC5655319__oncotarget-08-81686-g001
figlink: /pmc/articles/PMC5655319/figure/F1/
number: F1
caption: Increasing ERβ protein expression and nuclear translocation could be important
  for activation of the ERβ pathway. In addition, ERβ could stimulate Egr-1 transcription
  via the MEK1/Erk/Elk-1 cascade in glioma cells. Furthermore, ERβ agonist could enhance
  temozolomide sensitivity of glioma cells by inhibiting the PI3K/AKT/mTOR pathway.
  Ligand binding with ERβ could induce conformational changes that facilitate receptor
  dimerization to homodimers (ERβ/ERβ), translocation of dimers to the nucleus, and
  binding with co-regulatory proteins (CRP). This supra-molecular assembly thus may
  interact with the estrogen response element (ERE) in the promoter region of target
  genes. Furthermore, ERβ could also bind to the promoter region of PTEN through Sp1
  and increase PTEN transcription. The presence of various ERβ isoforms could add
  further complexity to the action of ERβ, which should be considered in clarifying
  the effects of ERβ in human glioma. However, it remains unclear which isoforms primarily
  exert anticancer effects in human glioma, and the distinct function of each ERβ
  isoform is unknown. More efforts should be directed toward clarifying the activation
  and agonist-induced dynamics of ERβ/ERβ homodimers and the distinct function of
  each ERβ isoform to design more potent ligands that selectively activate ERβ.
pmcid: PMC5655319
papertitle: Update on the therapeutic significance of estrogen receptor beta in malignant
  gliomas.
reftext: Yu-Long Lan, et al. Oncotarget. 2017 Oct 6;8(46):81686-81696.
pmc_ranked_result_index: '62538'
pathway_score: 0.9213974
filename: oncotarget-08-81686-g001.jpg
figtitle: Update on the therapeutic significance of estrogen receptor beta in malignant
  gliomas
year: '2017'
organisms:
- Homo sapiens
ndex: e90fd8a0-df0d-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5655319__oncotarget-08-81686-g001.html
  '@type': Dataset
  description: Increasing ERβ protein expression and nuclear translocation could be
    important for activation of the ERβ pathway. In addition, ERβ could stimulate
    Egr-1 transcription via the MEK1/Erk/Elk-1 cascade in glioma cells. Furthermore,
    ERβ agonist could enhance temozolomide sensitivity of glioma cells by inhibiting
    the PI3K/AKT/mTOR pathway. Ligand binding with ERβ could induce conformational
    changes that facilitate receptor dimerization to homodimers (ERβ/ERβ), translocation
    of dimers to the nucleus, and binding with co-regulatory proteins (CRP). This
    supra-molecular assembly thus may interact with the estrogen response element
    (ERE) in the promoter region of target genes. Furthermore, ERβ could also bind
    to the promoter region of PTEN through Sp1 and increase PTEN transcription. The
    presence of various ERβ isoforms could add further complexity to the action of
    ERβ, which should be considered in clarifying the effects of ERβ in human glioma.
    However, it remains unclear which isoforms primarily exert anticancer effects
    in human glioma, and the distinct function of each ERβ isoform is unknown. More
    efforts should be directed toward clarifying the activation and agonist-induced
    dynamics of ERβ/ERβ homodimers and the distinct function of each ERβ isoform to
    design more potent ligands that selectively activate ERβ.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CG
  - AKT3
  - AKT1
  - PIK3R3
  - PTEN
  - PIK3CA
  - AKT2
  - MAPK3
  - MAPK11
  - CRP
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R4
  - MAPK9
  - MAPK1
  - MAPK8
  - RAF1
  - EGR1
  - ARAF
  - TSN
  - ESR2
  - PIK3R6
  - ELK1
  - MTOR
  - MAPK10
  - MAPK14
  - SGPL1
  - MAP2K1
  - MAPK12
  - MAPK13
  - BRAF
  - LY500307
  - propionitrile
  - Salicylaldoxime
  - Toosendanin
  - Liquiritigenin
  - estrogen
  - Cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: CRP
  symbol: CRP
  source: hgnc_symbol
  hgnc_symbol: CRP
  entrez: '1401'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Egr-1
  symbol: EGR1
  source: hgnc_symbol
  hgnc_symbol: EGR1
  entrez: '1958'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: TSN
  symbol: TSN
  source: hgnc_symbol
  hgnc_symbol: TSN
  entrez: '7247'
- word: ERB
  symbol: ER-beta
  source: hgnc_alias_symbol
  hgnc_symbol: ESR2
  entrez: '2100'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Elk1
  symbol: ELK1
  source: hgnc_symbol
  hgnc_symbol: ELK1
  entrez: '2002'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: Spl
  symbol: SPL
  source: hgnc_alias_symbol
  hgnc_symbol: SGPL1
  entrez: '8879'
- word: MEK1
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
chemicals:
- word: LY500307
  source: MESH
  identifier: C000592024
- word: propionitrile
  source: MESH
  identifier: C005557
- word: Salicylaldoxime
  source: MESH
  identifier: C005704
- word: Toosendanin
  source: MESH
  identifier: C036454
- word: Liquiritigenin
  source: MESH
  identifier: C083152
- word: estrogen
  source: MESH
  identifier: D004967
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5655319__F1
redirect_from: /figures/PMC5655319__F1
figtype: Figure
---
